Category - Developments

Developments

Opus Genetics doses first patient with gene therapy in LCAS

Closely-held Opus Genetics dosed the first patient in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5, an adeno-associated virus 8 vector designed to precisely deliver a functional LCA5 gene to the outer...

September 7, 2023

Developments

Arcutis posts positive long-term roflumilast cream results in AD

Arcutis Biotherapeutics (NASDAQ:ARQT) reported positive interim results from the INTEGUMENT-OLE long-term, open-label study of roflumilast cream 0.15% in adults and children ages six years and older with atopic...

September 7, 2023

Developments

Cantor boosts biotech research with Josh Schimmer, Eric Schmidt

Cantor Fitzgerald bolstered its healthcare and biotech equity research team with the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D. “Having two of the most highly regarded analysts in the biotechnology...

September 6, 2023

Developments

Palisade Bio in GI-licensing deal with Giliant Pharma

Palisade Bio (NASDAQ:PALI) entered into a licensing agreement with closely-held Giliant Pharma for the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform...

September 6, 2023

Developments

Tonix fails Phase 2 pain study; holds out hope in fatigue

Tonix Pharmaceuticals Holding’s (NASDAQ:TNXP) TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at week 14 in the Phase 2 PREVAIL study. However, TNX-102 showed...

September 5, 2023

Developments

Plus Therapeutics initiates Part B of ReSPECT-LM Phase 1/2a trial for LM

Plus Therapeutics (NASDAQ:PSTV) treated the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium obisbemeda for the treatment of leptomeningeal metastases (LM) from...

September 5, 2023

Developments

Sage in reorganization to support launch of ZURZUVAE, advance pipeline

Sage Therapeutics (NASDAQ:SAGE) plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with...

August 31, 2023

Developments

Ampio Pharmaceuticals unveils reverse stock split

The board of Ampio Pharmaceuticals (NYSEA:AMPE) approved a 20-to-1 reverse stock split of the company’s common stock, to be effective at close on Sept. 11. Ampio’s common stock is expected to begin trading on a...

August 31, 2023

Developments

NRx Pharmaceuticals submits IND for chronic pain

NRx Pharmaceuticals (NASDAQ:NRXP) submitted an investigational new drug (IND) application to the FDA for the use of NRX-101 to treat chronic pain. The IND application leverages pioneering research on the use of D...

August 30, 2023

Developments

Outlook Therapeutics receives CRL in wet AMD

Outlook Therapeutics (NASDAQ:OTLK) received a complete response letter (CRL) to the company’s biologics license application (BLA) for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development...

August 30, 2023

Category - Developments

Opus Genetics doses first patient with gene therapy in LCAS

Arcutis posts positive long-term roflumilast cream results in AD

Cantor boosts biotech research with Josh Schimmer, Eric Schmidt

Palisade Bio in GI-licensing deal with Giliant Pharma

Tonix fails Phase 2 pain study; holds out hope in fatigue

Plus Therapeutics initiates Part B of ReSPECT-LM Phase 1/2a trial for LM

Sage in reorganization to support launch of ZURZUVAE, advance pipeline

Ampio Pharmaceuticals unveils reverse stock split

NRx Pharmaceuticals submits IND for chronic pain

Outlook Therapeutics receives CRL in wet AMD

General

More